patients 1 and 2), trichiasis (patients 2 and 4), and excessive tearing (patient 4). Patient 1 had phimosis that was corrected surgically.Discussion | In our experience using etanercept as treatment for patients with SJS-TEN, including in adults, we have made the following noteworthy observations (although these are only anecdotal). First, we found that a response to treatment with etanercept, namely decreased erythema of existing lesions and halting of progression of new lesions, often occurs 24 to 36 hours after administration. Borrowing from the dosing schedule successfully used in the randomized trial of adults by Wang et al, 5 we recommend considering a second dose in patients who continue to have fevers or notable erythematous and/or edematous skin lesions 36 to 48 hours after the initial dose. Second, patients treated with etanercept demonstrate remarkable time to reepithelialization, which corroborates previous findings comparing etanercept with corticosteroids. 5 Unfortunately this evidence is limited, particularly comparing etanercept with burn-level supportive care. Patient 3 demonstrated a remarkable halting of skin disease. We are not aware of any similar reports of preventing skin denudation in patients with SJS-TEN with early intervention using other immunosuppressive medications. Finally, the lack of adverse events (particularly infections) noted in patients in this series and others is encouraging, although further prospective randomized studies are needed. 4,5